Cohen Todd J, Klein Jeffrey
Director of Electrophysiology, Winthrop University Hospital, 259 First Street, Mineola, NY 11501, USA.
J Invasive Cardiol. 2002 Jan;14(1):48-53.
Cardiac resynchronization therapy (CRT) by means of biventricular pacing is a fairly new procedure that has recently been approved by the United States Food and Drug Administration. Many promising studies have been published that suggest CRT improves patient quality of life (based on the Minnesota Living with Heart Failure Quality of Life Questionnaire), increases distance walked in 6 minutes, improves oxygen uptake, lowers New York Heart Association classification, decreases QRS duration, increases left ventricular ejection fraction, and increases peak oxygen consumption. These studies include the Multisite Stimulation in Cardiomyopathies (MUSTIC), the Multicenter InSync Randomized Clinical Evaluation (MIRACLE), the Pacing Therapy for Congestive Heart Failure (PATH-CHF) multicenter trial, the Medtronic Inc. InSync study, the Ventak CHF/Contak CD study, Vigor CHF and a small study conducted by Alonso and colleagues. There are also a number of studies that are still being conducted, such as the COMPANION trial, which will provide further insight into the effectiveness of cardiac resynchronization therapy.
通过双心室起搏进行心脏再同步治疗（CRT）是一种相当新的治疗方法，最近已获得美国食品药品监督管理局的批准。许多有前景的研究已经发表，这些研究表明CRT可改善患者生活质量（基于明尼苏达心力衰竭生活质量问卷）、增加6分钟步行距离、改善氧摄取、降低纽约心脏协会分级、缩短QRS时限、提高左心室射血分数以及增加峰值耗氧量。这些研究包括心肌病多部位刺激（MUSTIC）、多中心同步随机临床评估（MIRACLE）、充血性心力衰竭起搏治疗（PATH-CHF）多中心试验、美敦力公司的同步研究、Ventak CHF/Contak CD研究、Vigor CHF以及阿隆索及其同事进行的一项小型研究。还有一些研究仍在进行中，例如COMPANION试验，该试验将进一步深入了解心脏再同步治疗的有效性。
